Introduction {#S1}
============

Obstructive sleep apnea (OSA) is a common breathing disorder which is identified by repetitive air flow reduction or cessation during sleep ([@B1]). The prevalence of OSA is estimated between 2 and 4%, varying with obesity status, gender, and age of populations ([@B2], [@B3]), usually caused by repetitive pharynx dysfunction which leads to apnea and hypopnea that result in the down regulation of blood oxygen levels ([@B4]). Oxygen desaturation triggered by chronic hypoxia further causes repetitive arousals and significant changes in both transmural and intra-thoracic pressure. This mechanism can increase the sympathetic activity and oxidative stress on the heart and intra-thoracic vessels, eventually resulting in vascular damages ([@B5]).

The severity of OSA can be classified by the Apnea--Hypopnea Index (AHI), evaluating the episode frequency of apnea/hypopnea in 1 h ([@B4]), which can be used to predict the relative risk of OSA. For instance, a 10% weight loss is predicted to be correlated with a 26% decrease in the AHI ([@B6]). OSA can also be evaluated by using the Epworth Sleepiness Scale (ESS), which considers both daytime sleepiness and the average sleep propensity ([@B2], [@B3]).

Continuous positive airway pressure (CPAP) therapy is a highly effective treatment option for OSA patients ([@B7]). Massive evidence suggests that CPAP therapy not only improves the AHI of OSA patients but also stabilizes their blood pressure levels ([@B8], [@B9]). Besides that, CPAP therapy is able to provide OSA patients with additional reduction in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) ([@B2], [@B3]). One major challenge of CPAP therapy is to identify a specifically effective pressure for individual OSA patient before CPAP therapy can be continuously applied to patients. This is usually achieved through standard manual titration and it is a time-consuming task ([@B10]). The above issue may be overcome by the auto-adjusting positive airway pressure (APAP) that only applies the lowest effective pressure to patients, and the corresponding pressure delivered is continuously adjusted depending on the residual symptoms detected on patients ([@B11]). CPAP also causes discomfort or nasal problems, and thus, it is not tolerable for all OSA patients ([@B12]). As a result, oral appliance (OA) therapy has been developed as an alternative to CPAP therapy for preventing airway collapse. APAP was reported to have equivalent performance in improving sleepiness compared to CPAP therapy ([@B13]). Although OA therapy is able to improve the AHI in OSA patients, several indexes of the OA therapy are inferior to those of CPAP therapy ([@B14]). Moreover, using mandibular advancement devices (an OA therapy) was associated with a reduction in SBP and DBP among OSA patients. However, such a benefit was not observed in OSA patients with CPAP therapy ([@B2], [@B3]).

Evidence in the current literature mainly comes from meta-analysis which was designed to answer the above questions. However, some conflicting results and conclusions appeared to be a major issue and this may arise from variations in study design, size, and participants ([@B6], [@B15], [@B16]). Thus, a network meta-analysis (NMA) with a large scale should be designed to integrate current MAs and clinical trials, increase the level of evidence and the credibility of individual studies as well as to provide clinicians with genuine consensus for the purpose of compensating the lack of head-to-head comparison.

Materials and Methods {#S2}
=====================

Identification of Trials {#S2-1}
------------------------

We comprehensively investigated the databases of the Cochrane Library, MEDLINE, and Embase. Key words and subject terms included "obstructive sleep apnea," "physical therapy modality," "continuous positive airway pressure," "auto-adjusting positive airway pressure," and "oral appliance." Controlled trials were identified using the Cochrane Highly Sensitive Search Strategy (sensitivity-maximizing and precision-maximizing version). The references of any related records were also screened in order to include additional qualified trials. Moreover, all articles screened and reviewed were published in English.

Inclusion Criteria {#S2-2}
------------------

Trials were supposed to meet the following standards: (1) controlled trials were preferred in our study selection. Other types of studies were also included if their research topics are relevant; (2) trials or studies must recruit patients who were older than 18 years and diagnosed with OSA. (3) OSA was specifically defined as AHI \> 5/h; (4) At least two of the following treatments were compared: CPAP, APAP, OA, and inactive control (IC, such as sham CPAP and placebo). (4) The outcomes of each study should include at least one of sleeping characteristics or blood pressure, including AHI, ESS, arterial oxygen saturation (SaO~2~), arousal index (AI), SBP, and DBP. AHI and ESS were assessed as primary outcomes, while the other outcomes were used as secondary outcomes.

Data Extraction {#S2-3}
---------------

We recorded basic characteristics of trials, including information of publications (author, year, and country), design of trials (RCT or non-RCT, and blinding), and follow-up durations. The changes of indexed, which were related to the quality of sleep and blood pressure, were seen as the most significant part of the trials. All the endpoints were continuous valuables, so the weighted mean difference (WMD) considering the trial size between different therapies was computed as well as corresponding sample SD.

Statistical Methods {#S2-4}
-------------------

STATA 12.0 software (Stata Corp, College Station, TX, USA) was used to perform traditional MA and WMD with corresponding 95% confidence interval (CI) were computed. We assessed heterogeneity among the included studies by Cochran's *Q* test ([@B17]) and the *I*^2^ test ([@B18]). If *P* \> 0.1 and *I*^2^ \< 50%, it suggested no significant heterogeneity existed and fixed-effects model was used. Otherwise, the random-effects model was applied if there was significant heterogeneity.

We combined direct and indirect evidence by NMA, a Bayesian framework based on Markov chain Monte Carlo method. STATA 12.0 software (Stata Corp, College Station, TX, USA) and WinBUGS software (MRC Bio-statistics Unit, Cambridge, UK) were applied as computational tools, which presented WMD with the corresponding 95% credible intervals (CrIs). In order to rank these therapies with respect to each clinical outcome, the surface of cumulative ranking curve area (SUCRA) was presented and generated a simulated ranking based on SUCRA values. For each comparison, the "design-by-treatment" interaction model was used to evaluate consistency between direct and indirect evidence. In the presence of significant inconsistency, the *P*-value of the "design-by-treatment" interaction model would be less than 0.05 and the result was displayed graphically in the node-splitting plots and net heat plots.

Risk of Bias Assessment {#S2-5}
-----------------------

We assessed the risk of bias by using the Cochrane Collaboration's criteria. Each study was assessed with respect to several types of bias (performance, detection, selection, attrition, and reporting bias) and classified as being at low, unclear, or high risk of bias for each potential source of bias. A "comparison adjusted" funnel plot was exhibited in order to illustrate publication bias, and the degree of symmetry in the funnel plot indicated whether the small-study effect was significant or not.

Results {#S3}
=======

Characteristics of Trials and Patients {#S3-1}
--------------------------------------

We retrieved and screened literature in the process showed in Figure [1](#F1){ref-type="fig"}A. A total of 1,612 records were identified through database searching and 481 were removed as duplicates. We excluded 714 records by reviewing their topics or abstracts. Another 333 records were removed after full-text reading since they contained incomplete data. A total of 84 studies were finally included and RCTs ([@B9], [@B11], [@B13], [@B19]--[@B99]). The pattern of evidence provided by studies was displayed in the network plot (Figure [1](#F1){ref-type="fig"}B). The size of nodes represents the sample size, and the thickness of lines indicates the number of trials comparing two therapies. CPAP was investigated in most trials. The baseline characteristics of studies were recorded in Table [1](#T1){ref-type="table"}. Trials collected in our study were conducted around the world, 41 in Europe, 20 in North America, 6 in Brazil, 5 in China, 8 in Australia, and 1 in New Zealand, Japan, India, and Pakistan, respectively.

![Flowchart **(A)** and network plot **(B)**. The network plot show direct comparison of different treatments, with node size corresponding to the sample size. The number of included studies for specific direct comparison decides the thickness of solid lines. Abbreviations: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance.](fneur-08-00289-g001){#F1}

###### 

Main characteristics of included studies.

  Reference                          Country       Design   Blinding     Follow-up   Treatment 1   Treatment 2                                                                                                                                                 
  ---------------------------------- ------------- -------- ------------ ----------- ------------- ------------- -------------- ------------ ------------- ------------- -------------- ------ ----- -------------- ------------ ------------- --------------- --------------
  Salord et al. ([@B19])             Spain         RCT      Double       --          CPAP          42            48.5 ± 8.6     26           45.7 ± 5      68.3 ± 11     7.9 ± 4.5      IC     38    44.6 ± 9.4     29           45.7 ± 5      68.3 ± 11       7.9 ± 4.5
  Pepin et al. ([@B11])              France        RCT      Double       4 months    CPAP          133           58 ± 3.5       70.8                       37.7 ± 6.5    9 ± 2          APAP   143   58 ± 3.2       69.6         --            37.7 ± 6.5      9 ± 2
  Paz et al. ([@B20])                USA           RCT      Double       1 months    IC            74            51.0 ± 11.7    52.7         37.3 ± 8.3    20.6 ± 6.2    10 ± 1.2       CPAP   75    51.7 ± 11.8    54.7         37.3 ± 8.3    20.6 ± 6.2      10 ± 1.2
  Pamidi et al. ([@B21])             Canada        RCT      Open-label   2 months    CPAP          26            53.8 ± 6.2     62           36.8 ± 7.8    34.2 ± 24.5   10 ± 5.9       OA     13    55.2 ± 8.4     77           36.8 ± 7.8    34.2 ± 24.5     10 ± 5.9
  Muxfeldt et al. ([@B22])           Brazil        RCT      Open-label   6 months    IC            60            60.2 ± 8.4     41.7         33.8 ± 5.8    39 ± 18       12 ± 6         CPAP   57    60.8 ± 8.0     37.9         33.8 ± 5.8    39 ± 18         12 ± 6
  Martinez-Garcia et al. ([@B23])    Spain         RCT      Open-label   --          CPAP          115           75.5 ± 3.8     63.5         33 ± 7.3      53.5 ± 15.6   9.6 ± 4        IC     109   75.6 ± 4.0     73.4         33 ± 7.3      53.5 ± 15.6     9.6 ± 4
  Huang et al. ([@B24])              China         RCT      Single       6 months    IC            37            62.7 ± 6.7     86.5         27.5 ± 2.6    28.7 ± 12.4   8.3 ± 3.4      CPAP   36    62.0 ± 6.8     77.8         27.5 ± 2.6    28.7 ± 12.4     8.3 ± 3.4
  Dalmases et al. ([@B25])           Spain         RCT      Open-label   3 months    CPAP          17            70.8 ± 5.1     64.7         32.8 ± 3.9    61.2 ± 17.9   7.94 ± 2.99    IC     16    71.9 ± 6.0     75           32.8 ± 3.9    61.16 ± 17.86   7.94 ± 2.99
  Woodson et al. ([@B26])            USA           RCT      Open-label   12 months   CPAP          23            57.1 ± 10      95.6         28.4 ± 2.4    31.3 ± 12.3   11.2 ± 5.3     IC     23    52.7 ± 10.4    82.6         28.4 ± 2.4    31.3 ± 12.3     11.2 ± 5.3
  Neikrug et al. ([@B27])            USA           RCT      Open-label   6 weeks     CPAP          19            66.7 ± 8.5     63.2         27.8 ± 4.7    21.1 ± 14.9   --             IC     19    67.7 ± 10.0    73.7         27.8 ± 4.7    21.1 ± 14.9     --
  Lloberes et al. ([@B28])           Spain         RCT      --           --          CPAP          36            58.3 ± 9.4     70.7         31.4 ± 4.9    50.1 ± 21.6   6.76 ± 3.7     IC     42    58.3 ± 9.4     70.7         31.4 ± 4.9    50.1 ± 21.6     6.76 ± 3.7
  Gottlieb et al. ([@B29])           USA           RCT      --           3 months    CPAP          90            63.5 ± 7.0     76           33 ± 5        25.4 ± 8.7    8 ± 3.8        IC     97    63.1 ± 7.7     78           33 ± 5        25.4 ± 8.7      8 ± 3.8
  Chasens et al. ([@B30])            USA           RCT      Double       1 month     CPAP          12            --             58                         50.2 ± 30.9   11.42 ± 4.62   IC     11    --             64           --            50.2 ± 30.9     11.42 ± 4.62
  Berry and Sriram ([@B13])          USA           RCT      --           --          APAP          78            57.7 ± 12.1    93.5         34.2 ± 5.8    --            15.2 ± 4.4     CPAP   70    59.7 ± 12.6    92.3         34.2 ± 5.8    --              15.2 ± 4.4
  Schutz et al. ([@B31])             Brazil        RCT      --           2 months    CPAP          9             38.62 ± 8.15   --           25.9 ± 5.31   25.1 ± 10.5   --             OA     9     42.33 ± 6.20   --           25.9 ± 5.31   25.1 ± 10.5     --
  Phillips et al. ([@B32])           Australia     RCT      Open-label   1 month     CPAP          56            49.5 ± 11.2    80.9         29.5 ± 5.5    25.6 ± 12.3   9.1 ± 4.2      OA     52    49.5 ± 11.2    80.9         29.5 ± 5.5    25.6 ± 12.3     9.1 ± 4.2
  Pedrosa et al. ([@B33])            Brazil        RCT      Open-label   6 months    CPAP          19            57.0 ± 2.1     74           36 ± 2.5      36 ± 6.5      12 ± 4         IC     16    55 ± 2         81           36 ± 2.5      36 ± 6.5        12 ± 4
  Martinez-Garcia et al. ([@B9])     Spain         RCT      Single       3 months    CPAP          98            57.8 ± 9.5     72.4         34.3 ± 5.7    41.3 ± 18.7   8.9 ± 4        IC     96    58.2 ± 9.6     64.6         34.3 ± 5.7    41.3 ± 18.7     8.9 ± 4
  Diaferia et al. ([@B34])           Brazil        RCT      --           3 months    IC            24            48.1 ± 11.2    100          27.4 ± 4.9    27.8 ± 20.3   12.7 ± 3       CPAP   27    48.1 ± 11.2    100          27.4 ± 4.9    27.8 ± 20.3     12.7 ± 3
  Andren et al. ([@B35])             Sweden        RCT      Single       3 months    OA            36            57.0 ± 8.0     83           30 ± 4        23 ± 16       11 ± 5.4       IC     36    59 ± 9         75           30 ± 4        23 ± 16         11 ± 5.4
  Sivam et al. ([@B36])              USA           RCT      Single       2 months    CPAP          27            47.0 ± 13.0    96.3         31.3 ± 3.8    37.2 ± 24.7   10 ± 4.8       IC     27    47 ± 13        96.3         31.3 ± 3.8    37.2 ± 24.7     10 ± 4.8
  Lee et al. ([@B37])                USA           RCT      Double       1 month     CPAP          26            48.3 ± 9.3     84.6         29.8 ± 4.6    36.7 ± 21.8   --             IC     30    48.2 ± 9.0     83.3         29.8 ± 4.6    36.7 ± 21.8     --
  Kushida et al. ([@B38])            USA           RCT      Double       6 months    CPAP          453           52.2 ± 12.2    65.3         32.4 ± 7.3    39.7 ± 24.9   10.07 ± 4.26   IC     422   50.8 ± 12.2    65.7         32.4 ± 7.3    39.7 ± 24.9     10.07 ± 4.26
  Hoyos et al. ([@B39])              Australia     RCT      Double       3 months    CPAP          34            51.0 ± 12.3    --           31.6 ± 5.3    38.5 ± 14.7   10 ± 4         IC     31    46.4 ± 10.4    --           31.6 ± 5.3    38.5 ± 14.7     10 ± 4
  Sharma et al. ([@B40])             India         RCT      Double       3 months    CPAP          86            45.1 ± 8.0     84           33.8 ± 4.7    47.9 ± 19.6   14.8 ± 3.7     IC     86    45 ± 8         95           33.8 ± 4.7    47.9 ± 19.6     14.8 ± 3.7
  Ryan et al. ([@B41])               Canada        RCT      Open-label   6 months    IC            22            60.7 ± 10.3    86.4         27.3 ± 5.8    33.3 ± 16.4   4.5 ± 2.1      CPAP   22    62.8 ± 12.8    72.7         27.3 ± 5.8    33.3 ± 16.4     4.5 ± 2.1
  Phillips et al. ([@B42])           Australia     RCT      Single       2 months    CPAP          37            49.4 ± 13.2    92.1         32.1 ± 4.3    41.2 ± 23.9   11.2 ± 4.9     IC     37    49 ± 13        92.1         32.1 ± 4.3    41.2 ± 23.9     11.2 ± 4.9
  Kohler et al. ([@B43])             Swiss         RCT      Single       1 month     CPAP          20            63.6 ± 5.1     95           32.9 ± 6.5    36 ± 17.3     13.8 ± 2.6     IC     21    61.8 ± 7.5     100          32.9 ± 6.5    36 ± 17.3       13.8 ± 2.6
  Drager et al. ([@B44])             Brazil        RCT      --           3 months    IC            18            44.1 ± 7.0     --           29 ± 2.6      58 ± 23       11 ± 5         CPAP   18    43 ± 7         --           29 ± 2.6      58 ± 23         11 ± 5
  Aarab et al. ([@B45])              Netherlands   RCT      Single       12 months   OA            21            50.4 ± 8.9     80.9         27.1 ± 3.1    21.4 ± 11     --             CPAP   22    54.9 ± 10.1    68.2         27.1 ± 3.1    21.4 ± 11       --
  Nguyen et al. ([@B46])             USA           RCT      Double       3 months    CPAP          10            52.9 ± 11.6    80           30.1 ± 4.7    38.8 ± 21.4   --             IC     10    53.9 ± 10.8    100          30.1 ± 4.7    38.8 ± 21.38    --
  Lozano et al. ([@B47])             Spain         RCT                   3 months    IC            35            59.2 ± 10.9    62.9         31.5 ± 5.6    46.8 ± 21.4   --             CPAP   29    59.2 ± 8.7     75.9         31.5 ± 5.6    46.78 ± 21.43   --
  Lam et al. ([@B48])                China         RCT      Double       1 week      CPAP          31            46.5 ± 10.8    27.8 ± 3.7   27.8 ± 3.8    33.4 ± 9.5    10.3 ± 4.9     IC     30    46.5 ± 10.8    27.2 ± 3.7   27.8 ± 3.8    33.4 ± 9.5      10.3 ± 4.9
  Durán-Cantolla et al. ([@B49])     Spain         RCT      Double       12 weeks    CPAP          169           53.2 ± 10.2    79           31.9 ± 5.7    39.8 ± 22.7   10.3 ± 4.2     IC     171   51.7 ± 10.8    84           31.9 ± 5.7    39.8 ± 22.7     10.3 ± 4.2
  Barbe et al. ([@B50])              Spain         RCT      Open-label   12 months   CPAP          179           55 ± 10        82           32 ± 5        43 ± 19       6.4 ± 2.4      IC     177   56 ± 10        85           32 ± 5        43 ± 19         6.4 ± 2.4
  Galetke et al. ([@B51])            Germany       RCT      --           6 weeks     CPAP          19            51.7 ± 10.4    94.7         32.1 ± 5.7    40.5 ± 21.5   11.3 ± 4.7     APAP   15    52.1 ± 9.2     86.7         32.1 ± 5.7    40.5 ± 21.5     11.3 ± 4.7
  Gagnadoux et al. ([@B52])          France        RCT      --           2 months    CPAP          59            50.3 ± 9.1     --           26.7 ± 3.5    34.2 ± 13     10.6 ± 4.5     OA     59    50.3 ± 9.1     --           26.7 ± 3.5    34.2 ± 13       10.6 ± 4.5
  Damjanovic et al. ([@B53])         Germany       RCT      --           9 months    APAP          50            57.6 ± 2.1     74           31.8 ± 8.5    41.8 ± 24.7   8.5 ± 5.6      CPAP   50    59.4 ± 2.1     82           31.8 ± 8.5    41.8 ± 24.7     8.5 ± 5.6
  Siccoli et al. ([@B54])            UK            RCT      --           1 month     IC            51            48.7 ± 10.6    --           34.5 ± 5      --            15.2 ± 4       CPAP   51    48.1 ± 9.5     --           34.5 ± 5      --              15.2 ± 4
  Ruttanaumpawan et al. ([@B55])     Canada        RCT      --           1 month     IC            14            60.5 ± 10.3    85.7         32.3 ± 8.6    51.3 ± 15.6   --             CPAP   19    59.0 ± 7.8     94.7         32.3 ± 8.6    51.3 ± 15.6     --
  Petri et al. ([@B56])              Denmark       RCT      Double       1 month     OA            27            50 ± 11        85.2         30.7 ± 5.2    39.1 ± 23.8   11.7 ± 4.3     IC     29    49 ± 10        79.3         30.7 ± 5.2    39.1 ± 23.8     11.7 ± 4.3
  Kohler et al. ([@B57])             UK            RCT      Double       1 month     IC            49            48.7 ± 10.6    --           34.5 ± 5      --            15.2 ± 4       CPAP   50    48.1 ± 9.5     --           34.5 ± 5      --              15.2 ± 4
  Hoekema et al. ([@B58])            Neherlands    RCT      Open-label   3 months    OA            47            --             --           --            39.4 ± 30.8   --             CPAP   47    --             --           --            39.4 ± 30.8     --
  Galetke et al. ([@B59])            Germany       RCT      Single       2 months    CPAP          20            --             --           --            32.9 ± 19.1   10.3 ± 5.7     APAP   20    --             --           --            32.9 ± 19.1     10.3 ± 5.7
  Egea et al. ([@B60])               Spain         RCT      --           3 months    CPAP          28            64 ± 0.9       96           31.7 ± 12.7   43 ± 23.3     8 ± 3.7        IC     32    63 ± 1.6       91           31.7 ± 12.7   43 ± 23.3       8 ± 3.7
  Cross et al. ([@B61])              UK            RCT      Double       6 weeks     IC            29            48 ± 2         95.6         37 ± 5.4      63 ± 26.9     --             CPAP   29    --             --           37 ± 5.4      63 ± 26.9       --
  West et al. ([@B62])               UK            RCT      Double       3 months    CPAP          19            57.8 ± 10.4                 36.6 ± 4.9    --            14.7 ± 3.5     IC     21    54.5 ± 9.4     --           36.6 ± 4.9    --              14.7 ± 3.5
  Smith et al. ([@B63])              UK            RCT      Double       6 weeks     IC            26            61 ± 8         88.5         31 ± 4        36 ± 23       10 ± 5         CPAP   26    61 ± 8         88.5         31 ± 4        36 ± 23         10 ± 5
  Patruno et al. ([@B64])            Italy         RCT      --           3 months    APAP          15            46.7 ± 11.6    80           36.4 ± 7.1    47.3 ± 14.7   15.8 ± 3.5     CPAP   16    47 ± 10.7      81.2         36.4 ± 7.1    47.3 ± 14.7     15.8 ± 3.5
  Martinez-Garcia et al. ([@B65])    Spain         --       --           3 months    CPAP          10            68.1 ± 7.8     52.2         35.1 ± 5.2    40 ± 19.7     7.4 ± 5.1      IC     23    72.2 ± 3.2     50           35.1 ± 5.2    40 ± 19.7       7.4 ± 5.1
  Lam et al. ([@B66])                China         RCT      --           10 weeks    CPAP          34            45 ± 1         79           27.6 ± 3.5    23.8 ± 11.1   12 ± 5.8       OA     34    45 ± 2         76           27.6 ± 3.5    23.8 ± 11.1     12 ± 5.8
  Haensel et al. ([@B67])            Netherlands   RCT      Double       2 weeks     CPAP          25            48.2 ± 10.2    80           33.1 ± 8.2    63.6 ± 29.1   --             IC     25    49.0 ± 10.6    80           33.1 ± 8.2    63.6 ± 29.1     --
  Fietze et al. ([@B68])             Germany       RCT      --           6 weeks     APAP          10            56.9 ± 9.3     100          32.6 ± 6.6    43.3 ± 30.2   --             CPAP   11    51.8 ± 13.5    90.9         32.6 ± 6.6    43.3 ± 30.2     --
  Drager et al. ([@B69])             Brazil        RCT      Double       4 months    IC            12            47 ± 6         --           29.7 ± 2.9    62 ± 22       13 ± 5         CPAP   12    44 ± 7         --           29.7 ± 2.9    62 ± 22         13 ± 5
  Coughlin et al. ([@B70])           UK            RCT      Single       6 weeks     CPAP          34            49.0 ± 8.3     --           36.1 ± 7.6    --            13.8 ± 4.9     IC     34    49.0 ± 8.3     --           36.1 ± 7.6    --              13.8 ± 4.9
  Robinson et al. ([@B71])           UK            RCT      Open-label   1 months    IC            16            54 ± 8         86.1         33.2 ± 5.3    --            5.3 ± 1        CPAP   16    54 ± 8         86.1         33.2 ± 5.3    --              5.3 ± 1
  Hui et al. ([@B72])                China         RCT      Single       3 months    CPAP          28            50.3 ± 1.6     78.6         27.5 ± 3.2    32.9 ± 16.9   10.7 ± 5.3     IC     28    51.2 ± 1.8     75           27.5 ± 3.2    32.9 ± 16.9     10.7 ± 5.3
  Campos-Rodriguez et al. ([@B73])   Spain         RCT      Double       1 months    CPAP          34            55.3 ± 9.6     55.8         35.7 ± 5.6    58.3 ± 24.6   15 ± 3.9       IC     34    58.0 ± 7.0     64.7         35.7 ± 5.6    58.3 ± 24.6     15 ± 3.9
  Usui et al. ([@B74])               Canada        RCT      --           1 months    OA            9             52.2 ± 4.1     77.8         31.3 ± 4.8    --            --             CPAP   8     55.0 ± 2.0     100          31.3 ± 4.8    --              --
  Marshall et al. ([@B75])           New Zealand   RCT      Double       3 weeks     IC            29            45 ± 9.8       75.9         32.3 ± 3.5    --            12.5 ± 4.3     CPAP   29    45 ± 9.8       75.9         32.3 ± 3.5    --              12.5 ± 4.3
  Blanco et al. ([@B76])             Spain         RCT      --           2 weeks     OA            8             55.6 ± 11.8    86.7         27.9 ± 4.3    33.8 ± 14.7   --             IC     7     55.6 ± 11.8    86.7         27.9 ± 4.3    33.8 ± 14.7     --
  Arias et al. ([@B77])              Spain         RCT      Double       3 months    IC            25            52 ± 13        100          30.5 ± 4      44 ± 27.5     --             CPAP   25    52 ± 13        100          30.5 ± 4      44 ± 27.5       --
  Masa et al. ([@B78])               Spain         RCT      Single       3 months    CPAP          126           51.0 ± 9.1     86.9         33.6 ± 8.4    61.8 ± 22     15.9 ± 3.5     APAP   119   52.2 ± 10.4    89.6         33.6 ± 8.4    61.8 ± 22       15.9 ± 3.5
  Mansfield et al. ([@B79])          Australia     RCT      Single       3 months    IC            21            57.5 ± 1.6     88.9         33.3 ± 5.5    26.6 ± 20.6   8.8 ± 4.1      CPAP   19    57.2 ± 1.7     100          33.3 ± 5.5    26.6 ± 20.6     8.8 ± 4.1
  Lloberes et al. ([@B80])           Spain         --       --           3 months    APAP          27            53.9 ± 7.7     81.5         32 ± 5.8      55.2 ± 24.2   13.3 ± 5.1     CPAP   30    58.6 ± 8.7     76.7         32 ± 5.8      55.2 ± 24.2     13.3 ± 5.1
  Ip et al. ([@B81])                 China         RCT      Single       3 months    CPAP          14            44.4 ± 6.9     100          29.6 ± 5.7    47.7 ± 15.3   --             IC     13    40.9 ± 11.1    100          29.6 ± 5.7    47.7 ± 15.3     --
  Hussain et al. ([@B82])            Pakistan      RCT      Single       1 week      APAP          10            44.9 ± 9.7     90           35.9 ± 12.9   47.2 ± 35.6   11.1 ± 6.4     CPAP   10    44.9 ± 9.7     90           35.9 ± 12.9   47.2 ± 35.6     11.1 ± 6.4
  Gotsopoulos et al. ([@B83])        Australia     RCT      Double       1 month     IC            33            48 ± 11        79.1         29.2 ± 27.6   27 ± 86.2     --             OA     31    48 ± 11        79.1         29.2 ± 27.6   27 ± 86.2       --
  Barnes et al. ([@B84])             Australia     RCT      --           3 months    CPAP          97            47.0 ± 0.9     78.38        31 ± 5.9      21.3 ± 12.8   10.7 ± 3.9     OA     99    47.0 ± 0.9     78.38        31 ± 5.91     21.3 ± 12.8     10.7 ± 3.9
  Woodson et al. ([@B85])            USA           RCT      Double       6 months    IC            30            46.0 ± 8.1     70           28.5 ± 4.2    15.4 ± 7.8    11.6 ± 3.5     CPAP   28    51.7 ± 8.6     75           28.5 ± 4.2    15.4 ± 7.8      11.6 ± 3.5
  Kaneko et al. ([@B86])             Japan         RCT      Single       1 month     IC            12            55.2 ± 3.6     83.3         32.3 ± 8.7    45.2 ± 18.3   5.7 ± 3.1      CPAP   12    55.9 ± 2.5     91.7         32.3 ± 8.7    45.2 ± 18.3     5.7 ± 3.1
  Becker et al. ([@B87])             Australia     RCT      Single       3 months    CPAP          16            54.4 ± 8.9     93.7         33.3 ± 5.1    62.5 ± 17.8   14.4 ± 2.5     IC     16    52.3 ± 8.4     87.5         33.3 ± 5.1    62.5 ± 17.8     14.4 ± 2.5
  Tan et al. ([@B88])                UK            RCT      --           2 months    CPAP          10            50.9 ± 10.1    83.3         31.9 ± 6.8    22.2 ± 9.6    13.4 ± 4.6     OA     14    50.9 ± 10.1    83.3         31.9 ± 6.8    22.2 ± 9.6      13.4 ± 4.6
  Randerath et al. ([@B89])          Germany       RCT      --           6 weeks     CPAP          20            56.5 ± 10.2    80           31.2 ± 6.4    17.5 ± 7.7    --             OA     20    56.5 ± 10.2    80           31.2 ± 6.4    17.5 ± 7.7      --
  Pepperell et al. ([@B90])          UK            RCT      Double       4 weeks     IC            59            51.0 ± 9.8     --           35.3 ± 6      --            16 ± 3.1       CPAP   59    50.1 ± 10.4    --           35.3 ± 6      --              16 ± 3.1
  Gotsopoulos et al. ([@B91])        Australia     RCT      Double       3 months    OA            73            48 ± 11        80.8         29 ± 4.5      --            --             IC     73    48 ± 11        80.8         29 ± 40.1     --              --
  Monasterio et al. ([@B92])         Spain         RCT      Single       6 months    IC            59            54 ± 9         91           29.5 ± 3.3    21 ± 6        13.2 ± 4.3     CPAP   66    53 ± 9         81           29.5 ± 3.3    21 ± 6          13.2 ± 4.3
  Bardwell et al. ([@B93])           USA           RCT      --           1 week      IC            16            48 ± 2.2       --           29.6 ± 5.2    --            --             CPAP   20    47 ± 1.9       --           29.6 ± 5.2    --              --
  Barbé et al. ([@B94])              Spain         RCT      Single       6 weeks     CPAP          29            54 ± 2         89.6         29 ± 5.4      54 ± 16.1     7 ± 2.1        IC     25    52 ± 2         96           29 ± 5.4      54 ± 16.1       7 ± 2.1
  Ballester et al. ([@B95])          Spain         RCT      --           3 months    IC            37            54 ± 1.5       86.5         34 ± 7.3      58 ± 18.2     11.4 ± 6.1     CPAP   68    53 ± 1.3       88.2         34 ± 7.3      58 ± 18.2       11.4 ± 6.1
  Redline et al. ([@B96])            USA           RCT      --           2 months    IC            46            49.2 ± 10.5    --           32 ± 8.5      --            10.6 ± 5.6     CPAP   51    48.1 ± 9.2     --           32 ± 8.5      --              10.6 ± 5.6
  Ferguson et al. ([@B97])           Canada        RCT      --           3 months    OA            24            44 ± 10.6      --           32 ± 8.2      25.3 ± 15.0   --             CPAP   24    44 ± 10.6      --           32 ± 8.2      25.3 ± 15       --
  Meurice et al. ([@B98])            Canada        RCT      Double       3 weeks     APAP          8             54 ± 11        100          34.2 ± 5.7    40.5 ± 17.7   15.2 ± 4.2     CPAP   8     54 ± 11        100          34.2 ± 5.7    40.5 ± 17.7     15.2 ± 4.2
  Ferguson et al. ([@B99])           Canada        RCT      --           4 months    OA            25            46.2 ± 10.9    88.9         30.4 ± 4.8    19.7 ± 13.8   --             CPAP   21    46.2 ± 10.9    88.9         30.4 ± 4.8    19.7 ± 13.8     --

*Treatment: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance*.

*Baseline: BMI, body mass index; AHI, Apnea--Hypopnea Index; ESS, Epworth Sleepiness Scale*.

Meta-analysis Result {#S3-2}
--------------------

We summarized pair-wise comparisons from MA and details of available data were shown in Table [2](#T2){ref-type="table"}. When compared with IC, CPAP showed better efficacy regarding all outcomes with WMD = 23.82, 95% CI: (18.49, 29.15) for AHI, WMD = 2.07, 95% CI: (1.51, 2.62) for ESS, WMD = 10.76, 95% CI: (7.84, 13.69) for AI, and WMD = −9.35, 95% CI: (−11.41, −7.29) for SaO~2~. In addition, CPAP could significantly reduce blood pressure than IC \[WMD = 1.89, 95% CI: (0.86, 2.92) for 24 h SBP; WMD = 1.70, CI: (1.13, 2.27) for 24 h DBP; WMD = 3.09, 95% CI: (2.18, 4.01) for dSBP; WMD = 1.98, 95% CI: (1.25, 2.70) for dDBP; and WMD = 4.22, 95% CI: (2.14, 6.30) for nSBP; WMD = 1.97, 95% CI: (0.81, 3.13) for nDBP\]. No statistical difference occurred in the comparison of CPAP versus APAP. However, CPAP presented greater reduction than OA in AHI \[WMD = −8.77, 95% CI: (−16.05, −1.50)\] and AI \[WMD = −2.59, 95% CI: (−4.91, −0.27)\], as well as blood pressure \[WMD = −9.57, 95% CI: (−11.34, −7.81) for 24 h SBP; WMD = −7.11, 95% CI: (−8.06, −6.15) for 24 h DBP; WMD = −7.87, 95% CI: (−13.28, −2.46) for dSBP\], and it led to an increase in SaO~2~ (WMD = 4.91, 95% CI: 2.85--6.97) versus OA. We found significant improvement with treatment of OA compared with IC, in the outcomes of AHI \[WMD = 9.40, 95% CI: (5.57, 13.23)\], ESS \[WMD = 1.15, 95% CI: (0.43, 1.87)\], AI \[WMD = 9.16, 95% CI: (2.70, 15.61)\], SaO~2~ \[WMD = −2.57, 95% CI: (−3.53, −1.61)\], 24 h SBP \[WMD = 1.64, 95% CI: (0.02, 3.26)\], and dDBP \[WMD = 2.15, 95% CI: (0.02, 4.28)\]. Generally, according to the MA results, CPAP and OA were proved to be more efficacious than IC, while there were no obvious difference in the effectiveness of CPAP and APAP. CPAP showed higher ability of reducing AHI, AI, and blood pressure than OA.

###### 

Direct pair-wise comparison results of obstructive sleep apnea.

  Outcomes   IC versus CPAP          CPAP versus APAP   CPAP versus OA        IC versus OA                                                         
  ---------- ----------------------- ------------------ --------------------- -------------- ----------------------- ------ ---------------------- ------
  AHI        23.82 (18.49, 29.15)    93.2               0.10 (−3.15, 3.34)    0.0            −8.77 (−16.05, −1.50)   96.2   9.40 (5.57, 13.23)     32.7
  ESS        2.07 (1.51, 2.62)       88.0               0.08 (−0.68, 0.85)    12.7           −0.31 (−1.02, 0.39)     0.0    1.15 (0.43, 1.87)      0.0
  AI         10.76 (7.84, 13.69)     14.9               0.32 (−3.05, 3.69)    0.0            −2.59 (−4.91, −0.27)    0.0    9.16 (2.70, 15.61)     78.9
  SaO~2~     −9.35 (−11.41, −7.29)   56.8               2.71 (−0.88, 6.29)    0.0            4.91 (2.85, 6.97)       60.0   −2.57 (−3.53, −1.61)   0.0
  24 h SBP   1.89 (0.86, 2.92)       23.3               --                    --             −9.57 (−11.34, −7.81)   0.0    1.64 (0.02, 3.26)      0.0
  24 h DBP   1.70 (1.13, 2.27)       0.0                --                    --             −7.11 (−8.06, −6.15)    0.0    1.18 (−0.02, 2.38)     0.0
  dSBP       3.09 (2.18, 4.01)       6.8                −1.70 (−5.11, 1.71)   --             −7.87 (−13.28, −2.46)   56.5   2.81 (−0.13, 5.74)     0.0
  dDBP       1.98 (1.25, 2.70)       14.4               −1.30 (−3.47, 0.87)   --             −2.40 (−8.01, 3.26)     --     2.15 (0.02, 4.28)      0.0
  nSBP       4.22 (2.14, 6.30)       68.0               −1.10 (−4.74, 2.54)   --             −3.90 (−12.88, 5.08)    --     1.06 (−2.09, 4.21)     0.0
  nDBP       1.97 (0.81, 3.13)       45.9               −1.30 (−3.42, 0.82)   --             −2.10 (−7.80, 3.60)     --     0.95 (−1.23, 3.14)     0.0

*Treatment: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance*.

*Outcomes: AHI, Apnea--Hypopnea Index; ESS, Epworth Sleepiness Scale; SaO~2~, arterial oxygen saturation; AI, arousal index; SBP, systolic blood pressure; DBP, diastolic blood pressure; d, daytime; n, nighttime; WMD, weighted mean difference; CI, confidence interval*.

Network Meta-analysis {#S3-3}
---------------------

Bayesian models allowed for more refined estimates of efficacy when participants were treated with APAP, CPAP, OA, and IC. Available data was recorded in Table [3](#T3){ref-type="table"} and displayed graphically in the forest plots in Figure [2](#F2){ref-type="fig"} for sleep characteristics and Figure [3](#F3){ref-type="fig"} for blood pressure. For the primary outcomes of AHI, APAP, CPAP, and OA all showed statistically reduction versus IC \[mean difference (MD) = −23.97, 95% CrI: (13.90, 34.31) for APAP; MD = −23.49, 95% CrI: (−28.68, −18.50) for CPAP; MD = −13.91, 95% CrI: (−21.01, −7.00) for OA\]. Significant decrease of AHI occurred in comparison of CPAP versus OA \[MD = −9.59, 95% CrI: (−15.40, −3.75) for CPAP\]. Similarly, statistical significance was observed in ESS for APAP, CPAP, and OA compared with IC, with MD = 2.19, 95% CrI: (0.89, 3.55) for APAP; MD = −2.04, 95%CrI: (1.54, 2.57) for CPAP; and MD = −1.58 95% CrI: (−2.89, −0.28) for OA. Similar observation was obtained in AI, with treatments of the three active interventions \[MD = 11.92, 95% CrI: (6.09, 18.97) for APAP versus IC; MD = 11.09, 95%CrI: (7.74, 15.20) for CPAP versus IC; MD = −8.32, 95% CrI: (−12.91, −4.55) for IC versus OA\]. Increase in SaO~2~ was exhibited in compares with IC \[MD = −6.08, 95% CrI: (−11.53, −1.04) for APAP versus IC; MD = −9.02, 95% CrI: (−11.33, −7.10) for CPAP versus IC; MD = 3.71, 95% CrI: (1.39, 6.42) for IC versus OA\]. In addition, we found great difference between OA and CPAP concerning SaO~2~ \[MD = −5.25, 95% CrI: (−7.64, −3.22)\]. For the secondary outcomes of blood pressure, more negative results were obtained. Data in 24 h SBP and 24 h DBP was merely available among CPAP, OA, and IC. Similar statistically significant results were presented in 24 h SBP \[MD = 2.38, 95% CrI: (0.92, 3.83) for IC; MD = 3.22, 95% CrI: (0.03, 6.34) for OA\] and 24 h DBP \[MD = 2.07, 95% CrI: (1.09, 3.02) for IC; MD = 2.70, 95% CrI: (0.56, 4.69) for OA\] when comparing with CPAP. We got complete information of all the interventions in terms of SBP and DBP during daytime and nighttime. A high similarity among the four plots was founded. CPAP contributed to significant reduction in daytime SBP \[MD = 3.70, 95% CrI: (1.98, 5.52) for IC versus CPAP\], daytime DBP \[MD = 2.04, 95% CrI: (1.32, 3.12) for IC versus CPAP\], nighttime SBP \[MD = 3.98, 95% CrI: (2.15, 6.04) for IC versus CPAP\] and nighttime DBP \[MD = −1.89, 95% CrI: (−3.50 to −0.72) versus IC\]. A comparison of OA versus CPAP in daytime SBP was also noted for indicating significant difference \[MD = 4.58, 95% CrI: (0.71, 7.98)\]. In all, based on the network results of primary outcomes, namely, AHI and ESS, significant improvement of APAP, CPAP, and OA were observed compared with IC, outcomes were at least in favor of CPAP when compared with OA, and APAP and CPAP could be classified as identical.

###### 

Network meta-analysis results of obstructive sleep apnea.

                                              APAP                        CPAP                       IC                           OA                      
  --------------- --------------------------- --------------------------- -------------------------- ---------------------------- ----------------------- ---------------
  ESS             APAP                        1                           0.48 (−8.29, 9.38)         **23.97 (13.90, 34.31)**     10.08 (−0.59, 20.68)    AHI
  CPAP            0.15 (−1.05, 1.39)          **1**                       **23.49 (18.50, 28.68)**   **9.59 (3.75, 15.40)**                               
  IC              **2.19 (0.89, 3.55)**       **2.04 (1.54, 2.57)**       **1**                      **−13.91 (−21.01, −7.00)**                           
  OA              0.61 (−1.13, 2.39)          0.46 (−0.82, 1.74)          **−1.58 (−2.89, −0.28)**   1                                                    
                                                                                                                                                          
  SaO~2~          APAP                        1                           0.84 (−4.04, 5.99)         **11.92 (6.08, 18.79)**      3.65 (−2.33, 9.59)      AI
  CPAP            2.94 (−1.82, 7.73)          1                           **11.09 (7.74, 15.2)**     2.80 (−0.63, 5.95)                                   
  IC              **−6.08 (−11.53, −1.04)**   **−9.02 (−11.33, −7.10)**   1                          **−8.32 (−12.91, −4.55)**                            
  OA              −2.34 (−7.70, 2.82)         **−5.25 (−7.64, −3.22)**    **3.71 (1.39, 6.42)**      1                                                    
                                                                                                                                                          
  24 h DBP        CPAP                        --                          1                          **2.38 (0.92, 3.83)**        **3.22 (0.03, 6.34)**   24 h SBP
  IC              --                          **2.07 (1.09, 3.02)**       1                          0.84 (−2.32, 3.89)                                   
  OA              --                          **2.7 (0.56, 4.69)**        0.64 (−1.47, 2.62)         1                                                    
                                                                                                                                                          
  Daytime DBP     APAP                        1                           **−1.71 (−8.22, 4.80)**    2.00 (−4.71, 8.79)           2.90 (−4.84, 10.03)     Daytime SBP
  CPAP            −1.23 (−4.13, 1.55)         1                           **3.71 (1.98, 5.52)**      **4.58 (0.71, 7.98)**                                
  IC              0.82 (−2.07, 3.87)          **2.04 (1.32, 3.12)**       1                          0.87 (−3.02, 4.25)                                   
  OA              −1.13 (−4.82, 2.74)         0.1 (−2.32, 2.75)           −1.97 (−4.30, 0.44)        1                                                    
                                                                                                                                                          
  Nighttime DBP   APAP                        1                           −1.12 (−7.74, 5.55)        2.83 (−3.91, 9.97)           1.77 (−6.43, 10.10)     Nighttime SBP
  CPAP            −1.29 (−5.37, 2.72)         1                           **3.98 (2.15, 6.04)**      2.89 (−1.95, 7.82)                                   
  IC              0.57 (−3.39, 5.12)          **1.89 (0.72, 3.50)**       1                          −1.09 (−5.72, 3.43)                                  
  OA              −0.31 (−5.21, 4.98)         1.00 (−2.02, 4.28)          −0.88 (−3.90, 1.94)        1                                                    

*Treatment: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance*.

*Outcomes: AHI, Apnea--Hypopnea Index; ESS, Epworth Sleepiness Scale; SaO~2~, arterial oxygen saturation; AI, arousal index; SBP, systolic blood pressure; DBP, diastolic blood pressure*.

*Bold font indicates statistically significant difference*.

![Forest plots regarding Apnea--Hypopnea Index, Epworth Sleepiness Scale, arousal index, and SaO~2~. Mean difference (MD) with 95% credible interval (CrIs) indicate the relative efficacy. Abbreviations: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance.](fneur-08-00289-g002){#F2}

![Forest plots regarding 24 h systolic blood pressure (SBP), 24 h diastolic blood pressure, daytime SBP, daytime SBP, nighttime SBP, and nighttime SBP. Mean difference (MD) with 95% credible interval (CrIs) indicate the relative efficacy. Abbreviations: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance.](fneur-08-00289-g003){#F3}

Ranking Scheme Based on SUCRA {#S3-4}
-----------------------------

The ranking probability of each treatment in terms of 10 outcomes was illustrated in Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}. CPAP and APAP were ranked top two in improving sleep characteristics, with similar ranking score in AHI (61.38% for CPAP and 62.79% for APAP) and ESS (61.40% for CPAP and 62.81% for APAP), best for APAP in AI (63.08%) and best for CPAP in SaO~2~ (72.27%). CPAP kept ranking as number one in reducing blood pressure and APAP became moderate. OA was regarded as a mild intervention, and IC was the last choice under all the circumstances. CPAP was recommended based on the ranking results.

![Stacked bar charts showing the rankings of four therapies for Apnea--Hypopnea Index, Epworth Sleepiness Scale, arousal index, and SaO~2~ at Nadir. The percentage number included in each pair of brackets indicates the cumulative ranking probability of the corresponding therapy. Abbreviations: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance.](fneur-08-00289-g004){#F4}

![Stacked bar charts showing the rankings of four therapies for 24 h systolic blood pressure (SBP), 24 h diastolic blood pressure, daytime SBP, daytime SBP, nighttime SBP, and nighttime SBP. The percentage number included in each pair of brackets indicates the cumulative ranking probability of the corresponding therapy. Abbreviations: CPAP, continuous positive airway pressure; APAP, auto-adjusting positive airway pressure; IC, inactive control; OA, oral appliance.](fneur-08-00289-g005){#F5}

Risk of Bias and Consistency {#S3-5}
----------------------------

Jadad scale of included studies was presented in Table S1 in Supplementary Material, which indicated medium--high quality and low risk of publication bias for all included studies. And the symmetry of the "comparison adjusted" funnel plots in Figures S1 and S2 in Supplementary Material had suggested that there was no remarkable publication bias. According to the node-splitting plots in Figure S3 in Supplementary Material, all the *P*-values were higher than 0.05, suggesting no significant inconsistency in terms of sleep characteristics. However, great inconsistency was obtained in the comparison of CPAP versus IC with respect to blood pressure, which indicated that indirect evidence had higher extent in reducing 24 h blood pressure, and the comparison of OA versus IC, in which indirect evidence provided adverse results (Figure S4 in Supplementary Material). Furthermore, the *P*-values showed that there was no consistency in the comparisons among CPAP, OA, and IC. The result of assessment for consistency was displayed in Figures S5 and S6 in Supplementary Material.

Discussion {#S4}
==========

In this study, NMA regarding AHI, ESS, AI, SaO~2~, and blood pressures was performed to evaluate the efficacy of CPAP, APAP, and OA in OSA patients. OSA is a detrimental disease since it results in not only sleepiness and snoring but also significant health problems such as atrial fibrillation ([@B100]).

As a first line therapy for OSA, CPAP was first recommended by the American College of Physicians ([@B100]), and Wright and White proposed in 2000 that the effect of CPAP on sleepiness is clinically significant since CPAP therapy is able to improve the life quality of OSA patients ([@B101]). Xu et al. confirmed that CPAP could also decrease the total cholesterol level, especially for younger and more obese patients who use CPAP in the long term, while the issue of lipid metabolism was not clinically significant ([@B102]).

Our NMA confirmed previous findings that CPAP is effective in improving AHI, ESS, AI, and SaO~2~. Ha et al. revealed that CPAP is superior to positional therapy in reducing the severity of sleep apnea ([@B103]). Previous studies have revealed that CPAP are capable of preventing upper airway collapse and arousals, as well as reducing oxidative stresses. Besides that, CPAP therapy can alleviate the corresponding symptoms of OSA such as excessive daytime sleepiness and snoring ([@B104], [@B105]). As Liu et al. concluded, CPAP was associated with significant reductions in SBP, DBP, and nocturnal DBP in patients with OSA and hypertension. Our research further revealed the positive effects of CPAP on nighttime DBP and daytime blood pressures ([@B106]). CPAP therapy significantly reduces BP in patients with OSA but the effect size may not be clinically significant. APAP presented a similar efficacy to CPAP on improving sleeping quality and reducing daytime sleepiness, since the comparisons between CPAP and APAP on AHI and ESS manifest neither statistical difference nor distinctive preferences. The above result is supported by Gao et al. who concluded that the effect of APAP on AHI improvements was identical to standard manual titration ([@B10]). Gao et al. also pointed out that the acceptance and compliance of automatic titrated method had the same performance as manual titration. Since APAP has the potential advantage in saving time and cost, automatic titration was also recommended as an alternative therapy in clinical practice ([@B10]). Despite we concluded that CPAP and APAP are identical in clinical outcomes, Xu et al. claimed that the use of APAP is slightly favored compared with fixed pressure CPAP in some aspects, such as compliance and patient preference, though the clinical relevance still requires further study ([@B107]). Despite the efficacy of APAP in sleeping quality, blood pressure outcomes are in favor of CPAP based on the SUCRA result, this preference might be the result of the relatively lower average pressure that APAP applies to OSA patients.

Similar to CPAP, OA exerts its function by relieving upper airway collapse during sleep through the modification of the position of mandible, tongue, and pharyngeal structures ([@B58]). Though inferior to CPAP, OA was also confirmed to be effective in improving symptoms and life qualities for patients with OSA. Okuno et al. supported our notion that compared with untreated patients, significant reduction in AHI and AI was found after OA therapy was applied ([@B14]). Due to its efficacy and cost saving features, OA has become increasingly popular and performed its clinical application as alternative therapy for CPAP ([@B58]). Yet, it should also be noted that the efficacy of OA is directly related to its type ([@B18]). Umemoto et al. found that fixed OAs are superior in treating OSA than twin-block appliances because of their ability to prevent mouth opening and reduce incisal overjet ([@B108]).

A high inconsistency between direct and indirect evidence was observed regarding the outcome of 24 h SBP, 24 h DBP, and daytime SBP, which concurs with Liu et al. that the beneficial effects of CPAP are inconsistent ([@B106]). Despite our conclusion that CPAP could significantly reduce all blood pressure outcomes, there existed studies that claimed non-significant decrease in BP was found ([@B109], [@B110]). This inconsistency might come from the discordance of OSA patient baseline characteristics and CPAP uses. Since studies reached agreement that the efficacy of CPAP increases with the severity of OSA, frequent apneic episodes may benefit the most from CPAP ([@B111]). Based on these conclusions, it is highly possible that results from different studies may vary due to the discordance in the baseline characteristics of different patients.

Our NMA originally combined conclusions on sleeping behavior and blood pressure; thus, a more overall efficacy of different therapy could be drawn. However, there also existed some limitations. Though an amount of 84 studies were included in our NMA, the sample size is still limited and resulted in the inconsistency discussed above. The included studies also presented deficient comparison between different therapy, such as APAP and OA. Moreover, the baseline of studies should be more unified to ensure the credibility and accuracy of our conclusions. Thus, larger comparison with better designed clinical trials is still required for a more comprehensive conclusion.

In all, CPAP, APAP, and OA are proved to be effective, which is supported by previous evidences. Based on primary outcomes, namely, AHI and ESS, significant improvement was observed compared with IC, outcomes are at least in favor of CPAP when compared with OA, and APAP and CPAP are classified as identical. Apart from ESS that represents reduction in daytime sleepiness, CPAP also presented significant improvements with respect to secondary outcomes like blood pressure. APAP tended to have slightly better performance than CPAP in AHI and ESS but are less promising in blood pressures on the basis of SUCRA. Our NMA identified CPAP as most efficacious treatment for OSA patients after synthetically evaluation on ESS, AHI, AI, SaO~2~, and blood pressures. Though inferior to CPAP and exerted no distinctive benefits on blood pressure, OA still manifested significant improvements in AHI and ESS compared with IC, indicating its feasibility as an alternative therapy for OSA patients. Larger clinical trials on the efficacy of CPAP on blood pressure for patients with OSA are needed for further investigation on the inconsistency observed.
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